Pulmonary Cell News Volume 10.34 | Sep 09 2021

    By
    Justin.choi
    -
    0
    21







    2021-09-09 | PULCN 10.34


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 10.34 – 9 September, 2021
    TOP STORY

    MAX Mutant Small-Cell Lung Cancers Exhibit Impaired Activities of MGA-Dependent Noncanonical Polycomb Repressive Complex

    Researchers found that MAX mutant small-cell lung cancer had ASCL1 or NEUROD1 or combined ASCL1/NEUROD1 characteristics and lacked MYC transcriptional activity.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Virtual Conference Exhibition: Organoids
    PUBLICATIONSRanked by the impact factor of the journal

    Endotoxin Stabilizes Protein Arginine Methyltransferase 4 (PRMT4) Protein Triggering Death of Lung Epithelia

    Scientists reported that a chromatin modulator protein arginine N-methyltransferase 4/coactivator-associated arginine methyltransferase 1 was elevated in human lung tissues with pneumonia and in experimental lung injury models.
    [Cell Death & Disease]

    Full Article

    PRMT7 Targets of Foxm1 Controls Alveolar Myofibroblast Proliferation and Differentiation during Alveologenesis

    Investigators provide evidence for PRMT7’s function in regulating alveolar myofibroblasts proliferation and differentiation during lung alveologenesis.
    [Cell Death & Disease]

    Abstract

    Smoking Shifts Human Small Airway Epithelium Club Cells toward a Lesser Differentiated Population

    The small airway epithelial of healthy nonsmokers and healthy cigarette smokers were evaluated by single-cell RNA sequencing, and unsupervised clustering revealed subpopulations of SCGCB1A1+KRT5loMUC5AC− club cells.
    [NPJ Genomic Medicine]

    Full Article

    GAB1 Alleviates Septic Lung Injury by Inhibiting the TLR4/ NF-κB Pathway

    The authors investigated the involvement of GRB2-associated binding protein 1 (GAB1) in septic lung injury. Lipopolysaccharide induced mouse model and A549 cell model were used to similar the septic lung injury.
    [Clinical and Experimental Pharmacology and Physiology]

    Abstract

    LINC01342 Silencing Upregulates microRNA-508-5p to Inhibit Progression of Lung Cancer by Reducing Cysteine-Rich Secretory Protein 3

    Researchers explored the role of LINC01342 in lung cancer (LC) development through the microRNA-508-5p/cysteine-rich secretory protein 3 axis. LINC01342, miR-508-5p, and CRISP3 expression in clinical samples and cell lines were determined, and their correlations in LC were analyzed.
    [Cell Death Discovery]

    Abstract

    Epithelial Membrane Protein 3 Regulates Lung Cancer Stem Cells via the TGF-β Signaling Pathway

    It was shown that epithelial membrane protein 3 (EMP3) expression was upregulated in NSCLC overexpressing aldehyde dehydrogenase 1. EMP3 was shown to be involved in cell proliferation, the formation of cancer stem cells and in epithelial‑mesenchymal transition.
    [International Journal of Oncology]

    Abstract

    Phillygenin Inhibits the Inflammation and Apoptosis of Pulmonary Epithelial Cells by Activating PPARγ Signaling via Downregulation of MMP8

    The authors investigated whether phillygenin could inhibit inflammation and apoptosis of pulmonary epithelial cells by activating peroxisome proliferator‑activated receptor γ (PPARγ) signaling.
    [Molecular Medicine Reports]

    Abstract

    DNA Methylation-Mediated Low Expression of CFTR Stimulates the Progression of Lung Adenocarcinoma

    There is an urgent need to probe the molecular mechanism of lung adenocarcinoma (LUAD) progression, so as to disclose prognostic and diagnostic markers for patients with LUAD. qRT-PCR revealed that CFTR was lowly expressed in LUAD cells.
    [Biochemical Genetics]

    Abstract

    Watch this webinar to learn the advantages of using primary human nasal epithelial cells to study Cystic Fibrosis.
    REVIEWS

    Pulmonary Histoplasmosis

    Scientists review clinical manifestations, radiological findings and treatment options according to the clinical form, as well as different diagnosis tools and new laboratory tests that have been recently developed and validated and are becoming widely available.
    [Mycopathologia]

    Abstract

    INDUSTRY AND POLICY NEWS

    HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

    HUTCHMED Limited and AstraZeneca PLChave initiated SANOVO, a China Phase III study of ORPATHYS®, an oral, potent, and highly selective MET tyrosine kinase inhibitor, in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (EGFR) TKI, TAGRISSO® as a first-line treatment in certain NSCLC patients whose tumors harbor EGFR mutation and overexpress MET.
    [HUTCHMED, Ltd.]

    Press Release

    FEATURED EVENT

    The NYSCF Conference – New York Stem Cell Foundation

    October 19 – 20, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    PhD Studentship – Lung Metastatic Niche

    CRUK Beatson Institute for Cancer Research – Glasgow, Scotland, United Kingdom

    Postdoctoral Scholar – Immunology of Lungs

    The University of Tennessee Health Science Center – Memphis, Tennessee, United States

    Research Associate – Senescence in Lung Tumor

    University of Cambridge – Cambridge, England, United Kingdom

    Assistant/Associate/Full Professor Tenure-Track – Aging and Inflammation

    Medical College of Georgia, Augusta University – Augusta, Georgia, United States

    Staff Researcher – Immune Responses after Heart and Lung Transplantation

    Washington University School of Medicine – St. Louis, Missouri, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter